Weesp, Netherlands

Johannes A Van Der Heyden


Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 61(Granted Patents)


Company Filing History:


Years Active: 1988-1995

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Johannes A Van Der Heyden

Introduction

Johannes A Van Der Heyden is a notable inventor based in Weesp, Netherlands. He has made significant contributions to the field of pharmacology, particularly in the development of compounds with psychotropic activity. With a total of 5 patents to his name, his work continues to influence the industry.

Latest Patents

One of his latest patents is focused on Bibyclic heteroacrylpiperazine derivatives having psychotropic activity. This invention relates to new compositions that comprise a compound of formula 1 as the active substance. The compounds of formula 1 are largely new, and the invention also pertains to these new compounds and their preparation through known synthesis methods. Another significant patent involves aryl-substituted (N-piperidinyl)methyl- and (N-piperidinyl)methylazoles. This invention highlights new aryl-substituted compounds that exhibit interesting pharmacological properties, particularly antipsychotic effects. These compounds can be synthesized using established methods and processed into compositions according to known techniques.

Career Highlights

Johannes A Van Der Heyden is associated with Duphar International Research Bv, where he continues to innovate in the field of pharmaceutical research. His work has been instrumental in advancing the understanding and development of psychotropic compounds.

Collaborations

He has collaborated with notable colleagues such as Cornelis G Kruse and Ineke Van Wijngaarden, contributing to a rich environment of research and innovation.

Conclusion

Johannes A Van Der Heyden's contributions to pharmacology through his patents and collaborations underscore his importance in the field. His innovative work continues to pave the way for new therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…